Product Images Donepezil Hydrochloride

The text provides a table showing the mean change in ADAS-cog score from baseline to 6, 12, and 18 weeks of drug treatment with Donepezil Hydrochloride Tablets at 5mg and 10mg, versus placebo. There is also reference to "Clinical Improvement" and "Clinical Decline". No further information is available.*

This is a graph displaying the cumulative percentage of patients receiving Donepezil Hydrochloride Tablets at different dosages and also the placebo, based on their change in ADAS-cog score. The ADAS-cog score is a measure of cognitive function in Alzheimer's disease patients. The graph shows that patients receiving the higher dose of Donepezil Hydrochloride Tablets (10 mg/day) experienced greater improvement in cognitive function compared to those receiving a lower dose (5 mg/day) or placebo. The x-axis shows the change from baseline (initial ADAS-cog score) and the y-axis shows the cumulative percentage of patients.*

Not available.*

This is a graph that shows the change from baseline in ADAS-cog (a test for assessing cognitive function in patients with Alzheimer's disease) over 12 weeks of drug treatment with either Donepezil Hydrochloride Tablets or a Placebo. The y-axis represents the mean (+SE) change in ADAS-cog score, while the x-axis represents the treatment period in weeks. The graph shows that both dosages of Donepezil Hydrochloride Tablets resulted in clinical improvement over the 12 weeks, while the Placebo group experienced clinical decline in cognitive function.*

The text provides a graph showing the cumulative percentage of patients and the SIB (Severe Impairment Battery) change from baseline for Donepezil Hydrochloride Tablets 10mg/day and Placebo. The graph shows that Donepezil Hydrochloride Tablets have a positive effect compared to a Placebo in improving SIB scores.*

This is a graph that shows the time course of change from baseline in ADCS-ADL-Severe score for patients who completed 6 months of treatment. The x-axis represents the time in months, while the y-axis represents the ADCS-ADL-Severe score. There are two lines: one for patients who received donepezil hydrochloride tablets 10 mg/day and one for patients who received a placebo. The graph suggests that patients who received donepezil hydrochloride tablets experienced some clinical improvement. However, a detailed description of the results cannot be given due to lack of context.*

This appears to be a graph with the title "Cumulative Percentage of Patients" with a Y-axis starting at 0 and ending at 100. The X-axis has a scale from 0-100 with marks at 15, 10, 5, 0, -5, and -10. The graph itself has two lines - one labeled "Donepezil Hydrochloride Tablets 10 mg/day" and the other labeled "Placebo" - both running from around 20% at the left side of the graph to 100% at the right side. Below the graph is a label reading "ADCS-ADL Change from Baseline".*